Beskrywing

The microbiome is the natural bacterial colonisation of the body – including skin, gut and stomach. The human microbiome refers to the spectrum of microbes (microbiota) that colonize humans. Microbiome therapies are currently focused on the prevention of C. difficile recurrence. This bacterium is often contracted in hospitals following antibiotic administration or a period of immunosuppression. The global microbiome therapeutics market is set to grow by US$ 918 miljoen tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 32.5% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix. Significant external funding for executing research and therapeutic innovation, increasing adoption of inorganic growth strategies in the market, growing demand for novel therapies to address the unmet needs of many diseases are expected to boost the market growth in the coming years.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for microbiome therapeutics. The global microbiome therapeutics market is segmented on the basis of target therapy area, region. By target therapy area, it is categorized into gastrointestinal diseases, infections, en ander. The gastrointestinal diseases segment held the largest market share in 2020. By region, the microbiome therapeutics market is divided into North America, Asiatiese Stille-Oseaan, Europa, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as 4D Pharma plc, AOBiome Therapeutics Inc., Assembly Biosciences Inc., Eligo Bioscience S.A.S, Finch Therapeutics Group Inc., MaaT Pharma SA, Quorum Innovations LLC, Rebiotix Inc. (Ferring Pharmaceuticals Group), Seres Therapeutics Inc., Synthetic Biologics, Vedanta Biosciences Inc..

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the microbiome therapeutics market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Target therapy area: gastrointestinal diseases, infections, en ander
Streek: Noord-Amerika, Asiatiese Stille-Oseaan, Europa, and Rest of the World (ROW)
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the global microbiome therapeutics market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the global microbiome therapeutics market looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Microbiome Therapeutics Market by Target Therapy Area
4.1 Gastrointestinal Diseases
4.2 Infections
4.3 Ander
5. Microbiome Therapeutics Market by Region
5.1 Noord-Amerika
5.2 Asiatiese Stille-Oseaan
5.3 Europa
5.4 Rest Of The World (Row)
6. Maatskappy profiele
6.1 4D Pharma plc
6.2 AOBiome Therapeutics, Inc.
6.3 Assembly Biosciences, Inc.
6.4 Eligo Bioscience S.A.S
6.5 Finch Therapeutics Group, Inc.
6.6 MaaT Pharma SA
6.7 Quorum Innovations, LLC
6.8 Rebiotix, Inc. (Ferring Pharmaceuticals Group)
6.9 Seres Therapeutics, Inc.
6.10 Synthetic Biologics
6.11 Vedanta Biosciences, Inc.
7. Bylaag
7.1 Oor StrategyHelix
7.2 Vrywaring